130 related articles for article (PubMed ID: 27755061)
1. LASSBio-1422: a new molecular scaffold with efficacy in animal models of schizophrenia and disorders of attention and cognition.
Betti AH; Antonio CB; Pompeu TE; Martins TS; Herzfeldt V; Stolz ED; Fraga CA; Barreiro E; Noël F; Rates SM
Behav Pharmacol; 2017 Feb; 28(1):48-62. PubMed ID: 27755061
[TBL] [Abstract][Full Text] [Related]
2. LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model.
Antonio CB; Betti AH; Herzfeldt V; Barreiro EJ; Fraga CA; Rates SM
Behav Pharmacol; 2016 Jun; 27(4):339-49. PubMed ID: 26513177
[TBL] [Abstract][Full Text] [Related]
3. New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia.
Neves G; Antonio CB; Betti AH; Pranke MA; Fraga CA; Barreiro EJ; Noël F; Rates SM
Behav Brain Res; 2013 Jan; 237():86-95. PubMed ID: 23000351
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579.
Pompeu TE; Alves FR; Figueiredo CD; Antonio CB; Herzfeldt V; Moura BC; Rates SM; Barreiro EJ; Fraga CA; Noël F
Eur J Med Chem; 2013 Aug; 66():122-34. PubMed ID: 23792350
[TBL] [Abstract][Full Text] [Related]
5. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
6. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D
Miyauchi M; Neugebauer NM; Meltzer HY
J Psychopharmacol; 2017 Apr; 31(4):442-452. PubMed ID: 28347261
[TBL] [Abstract][Full Text] [Related]
8. PT-31, a putative α2-adrenoceptor agonist, is effective in schizophrenia cognitive symptoms in mice.
Betti AH; Antonio CB; Herzfeldt V; Pitta MGDR; da Rocha Pitta I; do Rego JL; do Rego JC; Vaudry D; Rates SMK
Behav Pharmacol; 2019 Oct; 30(7):574-587. PubMed ID: 31206371
[TBL] [Abstract][Full Text] [Related]
9. Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
Neves G; Menegatti R; Antonio CB; Grazziottin LR; Vieira RO; Rates SM; Noël F; Barreiro EJ; Fraga CA
Bioorg Med Chem; 2010 Mar; 18(5):1925-35. PubMed ID: 20153652
[TBL] [Abstract][Full Text] [Related]
10. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
[TBL] [Abstract][Full Text] [Related]
11. The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent.
Wierońska JM; Sławińska A; Stachowicz K; Łasoń-Tyburkiewicz M; Gruca P; Papp M; Pilc A
Behav Brain Res; 2013 Nov; 256():298-304. PubMed ID: 23948211
[TBL] [Abstract][Full Text] [Related]
12. Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581.
Neves G; Kliemann M; Betti AH; Conrado DJ; Tasso L; Fraga CA; Barreiro EJ; Teresa Dalla Costa ; Rates SM
Pharmacol Biochem Behav; 2008 Mar; 89(1):23-30. PubMed ID: 18082872
[TBL] [Abstract][Full Text] [Related]
13. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
[TBL] [Abstract][Full Text] [Related]
14. Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia.
Sun X; Gou HY; Li F; Lu GY; Song R; Yang RF; Wu N; Su RB; Cong B; Li J
Acta Pharmacol Sin; 2016 Mar; 37(3):322-33. PubMed ID: 26775662
[TBL] [Abstract][Full Text] [Related]
15. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
[TBL] [Abstract][Full Text] [Related]
16. Biotransformation of LASSBio-579 and pharmacological evaluation of p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead compound.
Gomes TF; Pompeu TE; Rodrigues DA; Noël F; Menegatti R; Andrade CH; Sabino JR; Gil ES; Dalla Costa T; Betti AH; Antonio CB; Rates SM; Fraga CA; Barreiro EJ; de Oliveira V
Eur J Med Chem; 2013 Apr; 62():214-21. PubMed ID: 23353740
[TBL] [Abstract][Full Text] [Related]
17. The antipsychotic-like effects in rodents of YQA31 involve dopamine D3 and 5-HT1A receptor.
Gou HY; Sun X; Li F; Wang ZY; Wu N; Su RB; Cong B; Li J
Pharmacol Rep; 2017 Dec; 69(6):1125-1130. PubMed ID: 29128790
[TBL] [Abstract][Full Text] [Related]
18. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
19. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
[TBL] [Abstract][Full Text] [Related]
20. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
Depoortere R; Boulay D; Perrault G; Bergis O; Decobert M; Françon D; Jung M; Simiand J; Soubrié P; Scatton B
Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
